A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 73,307 shares of TGTX stock, worth $2.25 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
73,307
Previous 71,576 2.42%
Holding current value
$2.25 Million
Previous $1.09 Million 19.85%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$13.32 - $19.19 $23,056 - $33,217
1,731 Added 2.42%
73,307 $1.3 Million
Q1 2024

May 15, 2024

SELL
$13.02 - $21.3 $321,255 - $525,556
-24,674 Reduced 25.64%
71,576 $1.09 Million
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $165,844 - $466,995
24,827 Added 34.76%
96,250 $1.64 Million
Q3 2023

Nov 14, 2023

SELL
$8.36 - $26.5 $495,505 - $1.57 Million
-59,271 Reduced 45.35%
71,423 $597,000
Q2 2023

Aug 14, 2023

BUY
$15.48 - $35.0 $151,812 - $343,245
9,807 Added 8.11%
130,694 $3.25 Million
Q1 2023

May 15, 2023

SELL
$10.23 - $19.34 $56,827 - $107,433
-5,555 Reduced 4.39%
120,887 $1.82 Million
Q4 2022

Feb 14, 2023

BUY
$5.01 - $11.83 $633,474 - $1.5 Million
126,442 New
126,442 $1.5 Million
Q2 2021

Aug 16, 2021

SELL
$32.5 - $48.96 $349,570 - $526,613
-10,756 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$41.61 - $54.3 $955,365 - $1.25 Million
-22,960 Reduced 68.1%
10,756 $518,000
Q4 2020

Feb 16, 2021

BUY
$25.27 - $54.9 $404 - $878
16 Added 0.05%
33,716 $1.75 Million
Q3 2020

Nov 16, 2020

SELL
$18.49 - $27.24 $205,017 - $302,037
-11,088 Reduced 24.76%
33,700 $902,000
Q2 2020

Aug 13, 2020

BUY
$8.9 - $21.84 $398,613 - $978,169
44,788 New
44,788 $872,000
Q4 2019

Feb 14, 2020

SELL
$5.1 - $11.2 $56,635 - $124,375
-11,105 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$5.38 - $8.99 $59,744 - $99,833
11,105 New
11,105 $62,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.47B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.